What Is Sermorelin?

Sermorelin is the biologically active N-terminal 29-amino-acid fragment of endogenous human growth hormone-releasing hormone (GHRH(1-29)-NH₂). Native GHRH is a 44-amino-acid hypothalamic peptide; research established early that the first 29 residues retain the full biological activity needed for GH-releasing receptor (GHRHR) activation, making sermorelin a useful research tool and, historically, a clinical agent for GH deficiency diagnosis.

Unlike ghrelin-mimetic secretagogues such as ipamorelin (which targets the GHS-R1a receptor), sermorelin acts directly at the GHRH receptor expressed on pituitary somatotroph cells. This mechanistic distinction makes it a different type of research tool for studying the growth hormone axis — probing the GHRH pathway rather than the ghrelin pathway.

Mechanism of Action

Sermorelin binds to the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed predominantly on anterior pituitary somatotroph cells. Receptor activation stimulates adenylate cyclase, elevating intracellular cAMP, which in turn activates protein kinase A pathways. The downstream effect is stimulation of GH gene transcription and GH granule exocytosis.

Crucially, sermorelin’s GH-stimulating effect operates through the endogenous hypothalamic-pituitary feedback loop — GH release remains subject to normal somatostatin inhibition, preserving the physiological pulse pattern. This self-limiting mechanism is of interest in research models studying pituitary axis dynamics.

Sermorelin vs Ipamorelin and CJC-1295

Compound	Receptor Target	Mechanism Class	Half-Life
Sermorelin	GHRHR	GHRH analogue	~10–20 min
Ipamorelin	GHS-R1a	Ghrelin mimetic	~2 hours
CJC-1295	GHRHR	Modified GHRH analogue	~7 days (DAC form)

In research contexts, ipamorelin and sermorelin are sometimes studied in combination to examine potential synergistic effects through different receptor pathways — GHRHR and GHS-R1a acting simultaneously on somatotroph cells. See our Ipamorelin vs CJC-1295 vs Sermorelin comparison for more detail.

Research Areas

Sermorelin is studied in: growth hormone deficiency models (pituitary axis characterisation), pituitary somatotroph biology, neuroendocrine feedback loop research, age-related GH axis changes in animal models, and as a reference compound in GH secretagogue comparison studies. As the 29-AA fragment of natural GHRH, it provides a well-characterized GHRHR agonist standard for laboratory assays.

Storage

Store lyophilized sermorelin at −20°C, sealed and protected from moisture. Reconstitute with bacteriostatic water for laboratory use. Stable as lyophilate for extended periods under proper storage conditions. Reconstituted solutions should be used promptly or frozen at −80°C in aliquots.

FAQs

Is sermorelin the same as GHRH?

Not exactly. Sermorelin is a truncated 29-amino-acid fragment of endogenous GHRH, which is 44 amino acids. Research established that the first 29 residues are sufficient for full GHRHR binding and activation. Sermorelin is shorter and has slightly different stability characteristics compared to the full-length molecule.

How does sermorelin differ from ipamorelin?

Sermorelin acts on the GHRH receptor; ipamorelin acts on the ghrelin receptor (GHS-R1a). These are completely different receptor sites on the somatotroph cell. In research models, they represent distinct pathways for studying GH secretion regulation.

Where can I find published research on sermorelin?

PubMed contains a body of sermorelin literature spanning decades, including early clinical application as a GHRH analogue for GH deficiency assessment. Search “sermorelin” and “GHRH(1-29)” for the relevant preclinical and clinical publications.

Sermorelin is supplied by TrueCanPeptides for qualified in vitro laboratory research only. Not for human or animal administration. Not evaluated by Health Canada for any clinical use.

Related: Sermorelin 5mg | Ipamorelin vs CJC vs Sermorelin | What Is Ipamorelin? | What Is CJC-1295?